Uniunea Europeană -
română -
EMA (European Medicines Agency)
tabrecta
novartis europharm limited - capmatinib dihydrochloride monohydrate - carcinom, pulmonar non-celulă mică - agenți antineoplazici - tabrecta as monotherapy is indicated for the treatment of adult patients with advanced non small cell lung cancer (nsclc) harbouring alterations leading to mesenchymal epithelial transition factor gene exon 14 (metex14) skipping, who require systemic therapy following prior treatment with immunotherapy and/or platinum based chemotherapy.
România -
română -
ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)
tabrecta 150 mg
novartis pharma gmbh - germania - capmatinibum - compr. film. - 150mg - inhibitori de protein-kinaza alti inhibitori de protein kinaza
România -
română -
ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)
tabrecta 200 mg
novartis pharma gmbh - germania - capmatinibum - compr. film. - 200mg - inhibitori de protein-kinaza alti inhibitori de protein kinaza